Mraz Amerine & Associates Inc. Buys 4,209 Shares of Johnson & Johnson $JNJ

Key Points

• Mraz Amerine & Associates Inc. increased its stake in Johnson & Johnson by 17.4% during Q2, acquiring an additional 4,209 shares, bringing their total to 28,451 shares, valued at $4.35 million.
• Johnson & Johnson reported $2.77 earnings per share for the latest quarter, exceeding estimates, with revenue of $23.74 billion, a 5.8% increase year-over-year.
• The company declared a quarterly dividend of $1.30 per share, translating to an annualized yield of 2.7%, with a payout ratio of 55.61%.

Mraz Amerine & Associates Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,451 shares of the company's stock after purchasing an additional 4,209 shares during the period. Johnson & Johnson accounts for about 0.7% of Mraz Amerine & Associates Inc.'s holdings, making the stock its 22nd largest holding. Mraz Amerine & Associates Inc.'s holdings in Johnson & Johnson were worth $4,346,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Global Strategic Investment Solutions LLC boosted its stake in shares of Johnson & Johnson by 3.5% during the 2nd quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock worth $294,000 after acquiring an additional 65 shares in the last quarter. JSF Financial LLC raised its holdings in Johnson & Johnson by 2.2% in the 2nd quarter. JSF Financial LLC now owns 2,993 shares of the company's stock worth $457,000 after purchasing an additional 65 shares during the period. Elios Financial Group Inc. boosted its position in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC grew its holdings in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after purchasing an additional 67 shares during the period. Finally, MBA Advisors LLC raised its position in Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after acquiring an additional 68 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $189.75 on Thursday. The stock has a market cap of $456.98 billion, a PE ratio of 20.29, a P/E/G ratio of 2.41 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $190.22. The stock has a fifty day simple moving average of $177.49 and a 200-day simple moving average of $163.37. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the business earned $2.82 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson's payout ratio is presently 55.61%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. Morgan Stanley lifted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. HSBC increased their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Barclays boosted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research note on Friday, September 19th. Finally, Bank of America upped their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $189.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.